Project Grant R37CA300526
Award Date
3/17/25
Completion Date
2/28/30
Dollars Obligated
$557K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, NY 10032, USA
Similar Awards
This Project Grant award from the National Cancer Institute's (NCI) Cancer Biology Research program (CFDA 93.396) provides $583,127 to the Sloan-Kettering Institute for Cancer Research in New York, NY to conduct research aimed at understanding the mechanisms by which deficiency of the SMARCA4 gene promotes metastasis in lung adenocarcinoma.
The key research objectives are: 1) to elucidate how SMARCA4 deficiency in lung cancer regulates transcription and promotes metastasis, and 2) to...
This federal Project Grant award, valued at $267,527, was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to The University of Texas MD Anderson Cancer Center. The funding supports research aimed at overcoming resistance of SMARCA4-mutant lung cancer to KRAS G12C inhibitors by targeting SMARCA2, a known synthetic lethal interaction partner to SMARCA4. Key planned activities include investigating the mechanism of resistance, developing...
The National Cancer Institute (NCI) awarded a $703,410 Project Grant under the Cancer Treatment Research Program (CFDA 93.395) to New York University (NYU) School of Medicine. The 5-year grant, with a start date of January 16, 2025, supports research aimed at understanding and overcoming cellular plasticity mechanisms that enable lung cancer cells to adapt and become resistant to targeted therapies. Key objectives include:
Conducting a high-throughput screen to identify chromatin regulators...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides $3,787,956 in funding to New York University School of Medicine to conduct research aimed at improving understanding and treatment of small cell lung cancer (SCLC). The research will investigate the role of replication stress in SCLC tumor evolution and chemotherapy response, with the goal of developing more effective therapeutic strategies to combat acquired...
This $164,500 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research to identify targetable mechanisms of S100A9-mediated brain metastasis in EGFR-mutant lung cancer. The award recipients, the Trustees of Columbia University's Health Sciences Division, will employ a multidisciplinary approach to investigate how S100A9 expression and chromatin binding drive pro-metastatic gene expression and altered lipid metabolism to promote brain...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) provides $730,400 in funding to the Sloan-Kettering Institute for Cancer Research located in New York, NY. The goal of the proposed research is to determine how specific metabolic configurations in the tricarboxylic acid (TCA) cycle support malignant states in lung adenocarcinoma (LUAD) cancer. The research aims to 1) manipulate components of the canonical and non-canonical TCA cycles...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $122,834 to Duke University to conduct research on small cell lung cancer (SCLC). The study aims to investigate how inhibiting the ABL kinase enzyme, when combined with inhibition of MCT transporters, can induce metabolic dysregulation and ferroptosis-mediated cell death in SCLC cells. The research approaches include metabolic profiling, oxidative and glycolytic energy...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Research Manpower program (CFDA 93.398), supports research to develop improved risk stratification and clinical management for patients with non-small cell lung cancer (NSCLC). The $256,487 award to the Sloan-Kettering Institute for Cancer Research in New York, NY will fund the development of predictive models that integrate real-world data from circulating tumor DNA sequencing, radiomics, tumor genomic...
This $194,292 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) will support research by The Trustees of Columbia University in the City of New York to investigate the cell-intrinsic and cell-extrinsic mechanisms governing lung cancer cell plasticity during tumor evolution. Specifically, the researcher will leverage an innovative lineage tracing tool to quantitatively track cancer cell state transitions within the native tumor microenvironment....
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $450,429 to the Dana-Farber Cancer Institute, Inc. (DFCI) to advance immunotherapy approaches for non-small cell lung cancer (NSCLC). The key objectives are to define how the MUC1-C oncogenic protein promotes immune evasion in EGFR-mutant NSCLC, and to evaluate targeted therapies using anti-MUC1-C antibody-drug conjugates (ADCs) alone and in...